AUXILIUM PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY13 | FY12 | FY11 | FY10 | FY09 | |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Operating income | −$5.1M | −$1.9M | −$11.8M | −$8.6M | −$53.6M |
| Net income | — | — | −$11.8M | −$8.6M | −$53.5M |
| Total assets | $1.20B | $327.9M | $301.0M | $243.9M | $260.6M |
| Total liabilities | $949.7M | $128.0M | — | — | — |
| Equity | $251.5M | $199.9M | $84.4M | $94.4M | $120.5M |
| EPS (diluted) | $-0.17 | $-0.04 | $-0.69 | $-1.08 | — |
| Shares out. | 49.8M | 48.3M | 47.9M | 47.5M | 43.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2013- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- —
- Return on capital (ROCE)
- −0.5%
- Liabilities / assets
- 79.1%
- Debt / equity
- 3.78×
- Book value / share
- $5.05
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2013- Altman Z″ (distress)
- -0.44distress
- Piotroski F-Score
- 0/4weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 0 good- Altman Z″ in the distress zone
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJan 29, 2015
- Shareholder vote · Regulation FD disclosureJan 27, 2015
- Other material eventJan 21, 2015
- Other material eventJan 16, 2015
- Regulation FD disclosureDec 22, 2014
- Director / officer changeDec 19, 2014
- Other material eventDec 16, 2014
- Other material eventDec 12, 2014
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERMay 25, 2016
- SC 13G/AFeb 16, 2016
- SC TO-I/AAMENDMENT NO. 2 TO SCHEDULE TO-IMar 5, 2015
- SC 13G/AFeb 18, 2015
- SC 13GAQR CAPITAL MANAGEMENT LLCFeb 17, 2015
- SC 13G/AFeb 17, 2015
- SC 13G/AAMENDMENT 5 AUXILIUM PHARMACEUTICALS, INC.Feb 13, 2015
- SC 13GPENTWATER CAPITAL MANAGEMENT LP. SC 13G 12-31-2014(AUXILIUM PHARMACEUTICALS INC.Feb 10, 2015
- SC 13G/AFeb 10, 2015
- 15-12GFeb 9, 2015
- SC 13G/AFeb 4, 2015
- SC TO-I/AAMENDMENT NO. 1 TO SCHEDULE TO-IFeb 4, 2015
- SC TO-ISC-TO-IFeb 3, 2015
- 4Feb 2, 2015
- 8-K/AJan 30, 2015
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.